Clinical Trials
36 trialsNCT01174121 2026-05-22
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03412877 2026-05-22
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03449108 2026-05-22
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06083844 2026-05-18
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04931342 2026-03-10
BOUQUET
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT03029403 2025-09-19
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
University Health Network, Toronto
Phase 2 Active not recruiting
NCT03610490 2025-04-17
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03267680 2025-04-13
IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3
University of Southern California
Phase 2 Terminated
NCT06630611 2025-01-28
PragmaTIL
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting
NCT04102436 2024-03-12
Non-Viral TCR Gene Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT05243524 2023-09-13
AVALON
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2 Terminated
NCT00538031 2023-04-21
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
City of Hope Medical Center
Phase 2 Completed
NCT02978495 2022-12-28
Neoadjuvant Carboplatin in Triple Negative Breast Cancer
Barretos Cancer Hospital
Phase 2 Completed
NCT02562365 2022-07-27
ACTS
Fudan University
Phase 2 Unknown
NCT03836352 2022-03-31
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2 Active not recruiting
NCT02853318 2021-10-06
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT03192059 2021-09-08
PRIMMO
University Hospital, Ghent
Phase 2 Completed
NCT02948101 2019-03-12
PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00856180 2018-09-10
Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00002943 2018-08-10
Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00001426 2018-04-05
A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01585428 2018-03-07
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00652899 2017-12-28
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01105650 2017-12-28
MT2009-30
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00004221 2017-08-09
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
GOG Foundation
Phase 2 Terminated
NCT01306032 2017-04-26
Phase II ABT-888 With Cyclophosphamide
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00003852 2016-06-23
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
UNICANCER
Phase 2 Terminated
NCT01175772 2015-06-23
Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy
HaEmek Medical Center, Israel
Phase 2 Terminated
NCT00072566 2015-05-12
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025441 2013-12-04
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002489 2013-06-26
Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00002474 2013-05-30
Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003944 2013-04-17
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00003386 2013-04-11
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
GOG Foundation
Phase 2 Terminated
NCT00844506 2011-02-25
ISA-P53-CTX
University Medical Center Groningen
Phase 2 Completed
NCT00003269 2011-01-10
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
Scripps Health
Phase 2 Completed